Form 4: Lilly Endowment Sells $86M+ Eli Lilly Shares

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported multiple sales of common stock totaling 101,420 shares on October 8, 2025, reducing its direct beneficial ownership to 94,547,580 shares.

Summary

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co. (LLY), reported the sale of 101,420 shares of common stock.
• All transactions occurred on October 8, 2025, and were executed under a Rule 10b5-1 plan.
• The shares were sold in multiple transactions at weighted average prices ranging from $848.46 to $854.639 per share.
• The total approximate value of the shares sold is $86.22 million.
• Following these transactions, Lilly Endowment Inc. directly beneficially owns 94,547,580 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: A significant 10% owner sold a substantial number of shares, though it was executed under a Rule 10b5-1 plan, suggesting a pre-scheduled transaction rather than a reaction to new information. This makes the sentiment neutral to slightly negative, as it's a reduction in ownership but not necessarily a bearish signal.

Positives

• The sales were made pursuant to a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than a reactive sale based on new material non-public information.

Negatives

• A significant 10% owner reduced its direct beneficial ownership in Eli Lilly & Co. by 101,420 shares.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., sold 101,420 shares of the company's common stock on October 8, 2025. This transaction constitutes a related party dealing due to the Endowment's significant ownership stake.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a significant institutional investor, Lilly Endowment Inc., which could be interpreted as a portfolio rebalancing or profit-taking at current high valuations.
• The execution under a Rule 10b5-1 plan mitigates concerns that the sale is based on new negative material information, potentially reducing any adverse market reaction.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request to Eli Lilly & Company, any security holder, or the SEC staff.

Key Dates

Recommendation

The filing reports a significant sale of Eli Lilly & Co. common stock by Lilly Endowment Inc., a 10% owner, executed under a Rule 10b5-1 plan. While the sale is substantial in dollar value, it represents a small fraction of the Endowment's total holding and is a pre-scheduled transaction, not necessarily indicative of a change in fundamental outlook. The high sale prices suggest the Endowment is taking profits. Without additional information on the company's performance or strategic direction, this insider transaction alone does not warrant a change from a 'hold' position, as it's likely a portfolio rebalancing rather than a bearish signal.

Keywords

Eli Lilly, LLY, Lilly Endowment, insider trading, Form 4, stock sale, beneficial ownership, 10% owner, Rule 10b5-1